Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heparin neutralization by recombinant platelet factor 4 and protamine

J H Levy1, J G Cormack, A Morales

  • 1Department of Anesthesiology, Emory University School of Medicine, Atlanta, Georgia, USA.

Anesthesia and Analgesia
|July 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A rapid protocol for purification of total RNA for tissues collected from pigs at a slaughterhouse.

Genetics and molecular research : GMR·2011
Same author

Guidelines for the treatment of acute ischaemic stroke.

Neurologia (Barcelona, Spain)·2011
Same author

Analysing the effect of public health campaigns on reducing excess weight: a modelling approach for the Spanish Autonomous Region of the Community of Valencia.

Evaluation and program planning·2011
Same author

[Toward the appropriate use of teleradiology].

Radiologia·2011
Same author

Guidelines for the preventive treatment of ischaemic stroke and TIA (II). Recommendations according to aetiological sub-type.

Neurologia (Barcelona, Spain)·2011
Same author

Emergence of ageing-related changes in insulin secretion by pancreatic islets of male rat offspring of mothers fed a low-protein diet.

The British journal of nutrition·2011
Same journal

Operating Room Energy Usage Assessment at a Tertiary Academic Medical Center in the United States.

Anesthesia and analgesia·2026
Same journal

An Analysis of Quality Assurance Events in Nonoperating Room Anesthetizing Locations: A Qualitative Retrospective Cohort Study.

Anesthesia and analgesia·2026
Same journal

Advancing Perioperative Medication Safety: Consensus Recommendations From the 2024 Anesthesia Patient Safety Foundation Stoelting Conference.

Anesthesia and analgesia·2026
Same journal

Incomplete Recovery of Diaphragmatic Mechanics at a Train-of-Four Ratio of 0.90 to <0.95 Assessed by Dynamic Digital Radiography: A Proof-of-Concept Case Series.

Anesthesia and analgesia·2026
Same journal

Patients' Perspectives and Experiences of Participating in Anesthesia Research: A Qualitative Study.

Anesthesia and analgesia·2026
Same journal

Impact of Epidural-Related Maternal Fever on Neonatal Outcomes: A Single-Center Retrospective Case-Control Study Excluding Confirmed Histological Chorioamnionitis.

Anesthesia and analgesia·2026
See all related articles

Platelet factor 4 (PF4) effectively reverses heparin anticoagulation during cardiac surgery. This finding suggests recombinant PF4 as a potential alternative to protamine, particularly for patients with protamine allergies.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Biochemistry

Background:

  • Protamine is the sole available agent for reversing heparin-induced anticoagulation.
  • Platelet factor 4 (PF4), a naturally occurring platelet protein, possesses heparin-neutralizing properties.
  • Investigating novel anticoagulation reversal agents is crucial for patient safety during cardiac procedures.

Purpose of the Study:

  • To evaluate the efficacy of recombinant Platelet factor 4 (PF4) in reversing heparin anticoagulation in blood samples from cardiac surgery.
  • To compare the reversal capabilities of PF4 with protamine using activated clotting time (ACT) and thromboelastography.

Main Methods:

  • Blood samples from 33 cardiac surgery patients were analyzed for activated clotting time (ACT) and heparin levels.

Related Experiment Videos

  • Recombinant PF4 and protamine were added to heparinized blood at various ratios to determine reversal efficacy.
  • Viscoelastic analysis using thromboelastography was performed to assess clot formation dynamics.

    • Main Results:

    • Recombinant PF4 demonstrated statistically significant reversal of heparin anticoagulation at ratios of 3:1 and 3.5:1 (PF4:heparin).
    • Protamine reversal was effective at ratios of 1:1, 1.5:1, and 2:1 (protamine:heparin).
    • No significant differences were observed in viscoelastic clot formation between PF4 and protamine reversal.

    Conclusions:

    • Recombinant PF4 effectively reverses heparin-induced anticoagulation post-cardiopulmonary bypass at a 3.0:1 ratio.
    • PF4 presents a promising alternative to protamine, especially for patients experiencing protamine allergies.
    • Further clinical studies are warranted to confirm PF4's safety and efficacy in vivo.